We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.
- Authors
Mandai, Masaki; Hamanishi, Junzo; Abiko, Kaoru; Matsumura, Noriomi; Baba, Tsukasa; Konishi, Ikuo
- Abstract
Tumor immune therapy, especially anti-programmed cell death ligand-1/programmed cell death-1 (PD-L1/PD-1) treatment, is currently the focus of substantial attention. Ovarian cancer is the leading cause of mortality from gynecological malignancies, and novel treatment modalities, including immune therapy, are needed. However, a basic understanding of tumor immunity associated with the PD-L1/PD-1 signal has only recently emerged. In this review, we first discuss the importance of local tumor immunity, which affects the clinical outcome of ovarian cancer. We subsequently provide an overview of the basic findings regarding how the PD-L1/PD-1 signal influences local tumor immunity in ovarian cancer. Finally, we discuss what is needed to apply immune therapy in future clinical medicine.
- Subjects
OVARIAN cancer treatment; PROGRAMMED cell death 1 receptors; CANCER immunotherapy; GYNECOLOGIC cancer; CANCER-related mortality; TUMOR immunology
- Publication
International Journal of Clinical Oncology, 2016, Vol 21, Issue 3, p456
- ISSN
1341-9625
- Publication type
Article
- DOI
10.1007/s10147-016-0968-y